“The present situation has uncovered some structural weaknesses within the EU’s medicines supply chain and also a superior dependence on non-EU international locations for active pharmaceutical ingredients,” Kyriakides said. She recommended that supply chain concerns be resolved in an EU pharmaceutical approach envisioned to be launched by th